{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T13:53:35Z","timestamp":1753883615203,"version":"3.41.2"},"reference-count":11,"publisher":"The Endocrine Society","issue":"3","license":[{"start":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T00:00:00Z","timestamp":1739750400000},"content-version":"vor","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Parathyroid carcinoma (PC) is a rare cause of primary hyperparathyroidism with a highly variable clinical course. We report the case of a man with metastatic PC who presented with severe hypercalcemia, discovered incidentally after a fall. He underwent left upper parathyroidectomy with left thyroid lobectomy, and pathology confirmed PC. After a year of absence from follow-up, he developed recurrence with bilateral pulmonary metastases. Cinacalcet and denosumab were initiated due to persistent, severe hypercalcemia, followed by wedge resection and palliative radiotherapy of pulmonary metastases. Genetic analysis revealed no actionable pathogenic variants, but a BRCA1 mutation classified as a variant of unknown significance (VUS) was identified. He was started on olaparib, a poly adenosine diphosphate-ribose polymerase (PARP) inhibitor, 3 years after initial diagnosis. Following this, his PTH level declined by approximately 40% within 7 months. Subsequently, his PTH levels began increasing despite continuation of olaparib and, after 20 months, rose to his original PTH level prior to the initiation of therapy. This is a unique case of a patient with metastatic PC who had a BRCA1 VUS mutation, with initial partial reduction in PTH and calcium levels after PARP inhibitor treatment.<\/jats:p>","DOI":"10.1210\/jcemcr\/luaf007","type":"journal-article","created":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T20:16:44Z","timestamp":1736367404000},"source":"Crossref","is-referenced-by-count":0,"title":["Use of Olaparib in the Management of Metastatic Parathyroid Carcinoma With <i>BRCA1<\/i> Mutation"],"prefix":"10.1210","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9059-9146","authenticated-orcid":false,"given":"David","family":"Woodfield","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Diabetes, and Metabolism, Virginia Commonwealth University , Richmond, VA 23298 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trang","family":"Le","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetes, and Metabolism, Virginia Commonwealth University , Richmond, VA 23298 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grace","family":"Prince","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetes, and Metabolism, Virginia Commonwealth University , Richmond, VA 23298 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyun","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology, and Palliative Care, Virginia Commonwealth University , Richmond, VA 23298 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hetal","family":"Vachhani","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology, and Palliative Care, Virginia Commonwealth University , Richmond, VA 23298 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priyanka","family":"Majety","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetes, and Metabolism, Virginia Commonwealth University , Richmond, VA 23298 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","published-online":{"date-parts":[[2025,2,17]]},"reference":[{"key":"2025021712064616800_luaf007-B1","doi-asserted-by":"crossref","first-page":"102012","DOI":"10.1016\/j.ctrv.2020.102012","article-title":"Parathyroid cancer: an update","volume":"86","author":"Rodrigo","year":"2020","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"2025021712064616800_luaf007-B2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1200\/JOP.19.00540","article-title":"Contemporary evaluation and management of parathyroid carcinoma","volume":"17","author":"Fingeret","year":"2021","journal-title":"JCO Oncol Pract"},{"key":"2025021712064616800_luaf007-B3","doi-asserted-by":"crossref","first-page":"997009","DOI":"10.3389\/fonc.2022.997009","article-title":"Treatment and outcome of metastatic parathyroid carcinoma: a systematic review and pooled analysis of published cases","volume":"12","author":"Alberti","year":"2022","journal-title":"Front Oncol"},{"issue":"4","key":"2025021712064616800_luaf007-B4","doi-asserted-by":"crossref","first-page":"e220287","DOI":"10.1530\/ERC-22-0287","article-title":"Diagnosis and management of parathyroid carcinoma: a state-of-the-art review","volume":"30","author":"Roser","year":"2023","journal-title":"Endocr Relat Cancer"},{"issue":"9","key":"2025021712064616800_luaf007-B5","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1530\/ERC-20-0149","article-title":"Genotype of CDC73 germline mutation determines risk of parathyroid cancer","volume":"27","author":"Li","year":"2020","journal-title":"Endocr Relat Cancer"},{"issue":"8","key":"2025021712064616800_luaf007-B6","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1007\/s00432-019-02945-9","article-title":"Genetic profiling as a clinical tool in advanced parathyroid carcinoma","volume":"145","author":"Kutahyalioglu","year":"2019","journal-title":"J Cancer Res Clin Oncol"},{"issue":"3","key":"2025021712064616800_luaf007-B7","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s12020-023-03376-w","article-title":"Parathyroid carcinoma: molecular therapeutic targets","volume":"81","author":"Marini","year":"2023","journal-title":"Endocrine"},{"issue":"7","key":"2025021712064616800_luaf007-B8","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1002\/1878-0261.13398","article-title":"Targeted therapy of advanced parathyroid carcinoma guided by genomic and transcriptomic profiling","volume":"17","author":"Teleanu","year":"2023","journal-title":"Mol Oncol"},{"issue":"4","key":"2025021712064616800_luaf007-B9","first-page":"215","article-title":"PARP inhibitors: review of mechanisms of action and BRCA1\/2 mutation targeting","volume":"15","author":"Dziadkowiec","year":"2016","journal-title":"Prz Menopauzalny"},{"issue":"6","key":"2025021712064616800_luaf007-B10","doi-asserted-by":"crossref","first-page":"102041","DOI":"10.1016\/j.esmoop.2023.102041","article-title":"Efficacy of olaparib in advanced cancers with germline or somatic mutations in BRCA1, BRCA2, CHEK2 and ATM, a Belgian precision tumor-agnostic phase II study","volume":"8","author":"Joris","year":"2023","journal-title":"ESMO Open"},{"issue":"Suppl 15","key":"2025021712064616800_luaf007-B11","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.1200\/JCO.2019.37.15_suppl.3108","article-title":"Prediction of olaparib sensitivity for variants of unknown significance in homologous repair genes","volume":"37","author":"Chevrier","year":"2019","journal-title":"J Clin Oncol"}],"container-title":["JCEM Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/3\/3\/luaf007\/61921140\/luaf007.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/3\/3\/luaf007\/61921140\/luaf007.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T12:06:55Z","timestamp":1739794015000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcemcr\/article\/doi\/10.1210\/jcemcr\/luaf007\/8017679"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,10]]},"references-count":11,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,2,10]]}},"URL":"https:\/\/doi.org\/10.1210\/jcemcr\/luaf007","relation":{},"ISSN":["2755-1520"],"issn-type":[{"type":"electronic","value":"2755-1520"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2025,2,10]]},"article-number":"luaf007"}}